NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP
· Real-Time Price · USD
2.00
-0.12 (-5.66%)
At close: Oct 03, 2025, 3:59 PM
1.98
-0.75%
After-hours: Oct 03, 2025, 07:41 PM EDT
NLS Pharmaceutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 1.67M | 552.76K | 897.68K | 1.65M | 8.95M | 1.35M | 5.43M | 7.09M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 283.00 | n/a | 16.89K | 12.56K | 12.14K | 11.73K | 12.04K | n/a |
Receivables | 400K | 31.57K | 10.66K | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | -64.28K | -41.24K | -59.83K | -38.55K | -43.08K |
Other Current Assets | 49.48K | 310.85K | 845.7K | 102.1K | n/a | n/a | n/a | n/a |
Total Current Assets | 2.23M | 1.19M | 1.82M | 2.25M | 9.25M | 2.02M | 5.72M | 8.24M |
Property-Plant & Equipment | 7.29K | 990.00 | 6.69K | 12.4K | 18.1K | 23.81K | 29.51K | 27.73K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 7.57K | 990.00 | 23.58K | 24.95K | 30.25K | 35.54K | 41.55K | 27.73K |
Total Assets | 2.23M | 1.19M | 1.85M | 2.27M | 9.28M | 2.06M | 5.76M | 8.27M |
Account Payables | 515.49K | 4.58M | 4.63M | 3.11M | 2.37M | 2.52M | 1.74M | 527.2K |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 2.5B | n/a |
Short-Term Debt | n/a | 1.71M | 1.63M | n/a | n/a | 354.34K | n/a | n/a |
Other Current Liabilities | n/a | 277.77K | 112.64K | -19.32K | 8.89K | 33.24K | 10.08K | n/a |
Total Current Liabilities | 826.76K | 7.72M | 7.92M | 3.89M | 3.36M | 3.41M | 2.4M | 1.19M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | 243.63K | 260.68K | 164.62K | 136.12K | 188.76K | 318.89K | 327.32K |
Total Long-Term Liabilities | n/a | 2.74M | 2.76M | 2.66M | 2.64M | 2.69M | 2.82M | 2.83M |
Total Liabilities | 826.76K | 10.46M | 10.68M | 6.56M | 6M | 6.1M | 5.22M | 4.02M |
Total Debt | n/a | 1.71M | 1.63M | n/a | n/a | 354.34K | n/a | n/a |
Book Value | 1.41M | -9.27M | -8.83M | -4.29M | 3.28M | -4.04M | 542.39K | 4.25M |
Book Value Per Share | 25.57 | -0.22 | -0.27 | -0.11 | 0.12 | -0.25 | 0.04 | 0.38 |
Common Stock | 166.35K | 808.55K | 733.41K | 733.41K | 668.55K | 411.27K | 344.44K | 259.73K |
Retained Earnings | -74.43M | -72.41M | -70.37M | -65.81M | -58.2M | -50.35M | -41.71M | -34.36M |
Comprehensive Income | 108.85K | 4.21K | -158.07K | -66.22K | -50.79K | -32.71K | -151.74K | -179.85K |
Shareholders Equity | 1.41M | -9.27M | -8.83M | -4.29M | 3.28M | -4.04M | 542.39K | 4.25M |
Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |